Tvardi Therapeutics (TVRD) Accumulated Expenses (2013 - 2026)
Tvardi Therapeutics (TVRD) posted Accumulated Expenses of $6.5 million for Q1 2026, up 402.54% sequentially from $1.3 million in Q4 2025, and up 975.58% YoY from $606000.0 in Q1 2025.
Tvardi Therapeutics (TVRD) Accumulated Expenses (2013 - 2026) Analysis & Trends
Tvardi Therapeutics has reported Accumulated Expenses for 13 years, with the latest figure at $6.5 million in Q1 2026.
- Quarterly Accumulated Expenses rose 975.58% year-over-year to $6.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.5 million (up 975.58% YoY) and the FY2025 annual result came in at $1.3 million, up 13.57% from the prior year.
- Accumulated Expenses grew to $6.5 million in Q1 2026 per TVRD's latest filing, from $1.3 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $6.5 million in Q4 2023 and troughed at $606000.0 in Q1 2025.
- A 5-year average of $2.9 million and a median of $2.4 million in 2022 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2026: Accumulated Expenses sank 82.48% in 2024, then soared 975.58% in 2026.
- Over 5 years, Accumulated Expenses stood at $5.2 million in 2022, then gained by 24.91% to $6.5 million in 2023, then tumbled by 82.48% to $1.1 million in 2024, then rose by 13.57% to $1.3 million in 2025, then jumped by 402.54% to $6.5 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $6.5 million, $1.3 million, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.52 Mn |
| Dec 31, 2025 | 1.30 Mn |
| Sep 30, 2025 | 1.01 Mn |
| Jun 30, 2025 | 740,000.00 |
| Mar 31, 2025 | 606,000.00 |
| Dec 31, 2024 | 1.14 Mn |
| Sep 30, 2024 | 1.17 Mn |
| Jun 30, 2024 | 1.21 Mn |
| Mar 31, 2024 | 2.06 Mn |
| Dec 31, 2023 | 6.52 Mn |
| Sep 30, 2023 | 5.37 Mn |
| Jun 30, 2023 | 4.20 Mn |
| Mar 31, 2023 | 2.95 Mn |
| Dec 31, 2022 | 5.22 Mn |
| Sep 30, 2022 | 4.23 Mn |
| Jun 30, 2022 | 3.35 Mn |
| Mar 31, 2022 | 2.41 Mn |
| Dec 31, 2021 | 4.96 Mn |
| Sep 30, 2021 | 4.13 Mn |
| Jun 30, 2021 | 3.15 Mn |